Seeking Alpha

Henry McCusker's  Instablog

Henry McCusker
Send Message
Analyst, Journalist and Publisher ... Henry enters his twelve (12) year at Scimitar's RegMedicine Investors which aggregates, curates and creates bottom-line content weeding of regenerative medicine and cell therapy news to provide a customized, vetted selection of relevant and high-impact... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
  • Aastrom (ASTM) Q4/12 And FY12 Results 0 comments
    Mar 18, 2013 6:16 PM

    A net loss of $7.9 M, or $0.18 per share

    A Q4/12 net loss of $7.9 M, or $0.18 per share compared to a net loss of $2.8 M or $0.07 per share for Q4/11. The increase in net loss is primarily due to the non-cash change in the fair value of warrants, the non-cash accretion of convertible preferred stock and increases in R&D expenses. A FY12 net loss of $33.5 M, or $0.81 per share compared to a net loss of $19.7 M or $0.51 per share for the FY11.

    R&D expenses increased to $6 M from $5.9 M for Q4/11. The increase in R&D expenses was primarily attributable to the launch of the P2b ixCELL-DCM clinical study and the ongoing P3 REVIVE clinical program for ixmyelocel-T, as well as an increase in non-cash stock-based compensation expenses. G&A expenses decreased to $1.6 M compared to $1.9 M for Q4/11. Q4/12 includes a reversal of nearly $1 M in non-cash stock based compensation expense related to stock option forfeitures. This was offset by an increase in non-cash stock based compensation expense before the <stock option> forfeiture(s) adjustment and slightly higher legal and consulting costs. Other income was $1 M compared to $5 M for Q4/11. The fluctuations are due to non-cash changes in the fair value of the outstanding warrants, primarily driven by the change in the fair market value of the common stock. For Q4/12, cash used for operations was $7.3 M. Loss from operations decreased to $7.6 M from $7.8 M in Q4/11. The quarterly net loss increased to $6.65 M from $2.79 M in Q4/11. ASTM used the ATM for approximately $3 M to date with $18+ M left if and as needed. Shares used in computing the net loss were 43.78 M.

    • As of 12/31/12, ASTM had $13.6 M in cash and cash equivalents.

    FY12 Results: A net loss of $33.5 M, or $0.81 per share compared to $19.7 M or $0.51 per share for the FY11. R&D expenses were $26.0 M $21.3 M for FY11. G&A expenses were $7.8 M compared to $7.7 M for FY11. Other income was $4.3 M compared to $9.4 M for FY11. For FY 12 cash used for operations were $29.5 M. Shares used in computing the new loss were 38.63 M.

    Q4/12 and FY12 Highlights:

    • Appointed Nick Colangelo as President and CEO;
    • Initiated patient enrollment in the P2b ixCELL-DCM clinical study of ixmyelocel-T in patients with ischemic dilated cardiomyopathy;
    • Increased the number of clinical investigators and sites participating in the P3 REVIVE clinical study of ixmyelocel-T in patients with CLI;
    • Appointed Joyce Frey-Vasconcells, PhD, to the SAB.

    The Bottom Line: Q4 EPS of -$0.18 beats by $0.05 but, losses were 2.6 X <the previous> FY11 primarily due to increased trial costs which are included in R&D expenses. ASTM's new CEO is focused on … completing enrollment in the P2b ixCELL-DCM study which is … accelerating the rate of enrollments in the P3 REVIVE study with more viable sites < just north of 100 while eliminating some sites>, addressing its capital requirements initially through cost containment and controlling its clinical programs.

    The new CEO has inherited a "big plate of issues" and if you think he was hesitant on the call - he has … only had the "bulls eye" on his back for a few days and he understands his transition days are limited to his current 8 day a week schedule - investors WILL be well served!!

    ASTM was UP at the close … +$0.03 or +2.34% at $1.31 … pre the earnings announcement … this pricing STILL DOES NOT reflect a late stage P3 trial status and the potential of partnering initiatives. ASTM traded in a lower mid-day range of $1.25 - $1.31 with moderate 273 K volume … compared to Friday's closing of $1.28 with moderate volume of 194.9 K shares. 9.4% of shares are held by institutions and 0.56% is held by insiders. The 50 day moving average is $1.28 while the 200 day average has trended to $1.41. Institutional holdings are running at 15.90% but, the short position is 7.5% of 43.78 M float of the 42.78 M shares outstanding.

    As usual <in a review of the past 3-4 announcements …there will be selling "trough" post the earnings release- the stock is down <in the after-market> $0.04 or -3.05% to $1.27. So hold on … still a "Speculative BUY" … but, a lot off issues - trials, cash and partnering need to be addressed by the new CEO!

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Back To Henry McCusker's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.